| Literature DB >> 36187226 |
Peining Li1, Barbara Dupont2, Qiping Hu3, Marco Crimi4,5, Yiping Shen6, Igor Lebedev7, Thomas Liehr8.
Abstract
Human ring chromosomes (RCs) are rare diseases with an estimated newborn incidence of 1/50,000 and an annual occurrence of 2,800 patients globally. Over the past 60 years, banding cytogenetics, fluorescence in situ hybridization (FISH), chromosome microarray analysis (CMA), and whole-genome sequencing (WGS) has been used to detect an RC and further characterize its genomic alterations. Ring syndrome featuring sever growth retardation and variable intellectual disability has been considered as general clinical presentations for all RCs due to the cellular losses from the dynamic mosaicism of RC instability through mitosis. Cytogenomic heterogeneity ranging from simple complete RCs to complex rearranged RCs and variable RC intolerance with different relative frequencies have been observed. Clinical heterogeneity, including chromosome-specific deletion and duplication syndromes, gene-related organ and tissue defects, cancer predisposition to different types of tumors, and reproductive failure, has been reported in the literature. However, the patients with RCs reported in the literature accounted for less than 1% of its occurrence. Current diagnostic practice lacks laboratory standards for analyzing cellular behavior and genomic imbalances of RCs to evaluate the compound effects on patients. Under-representation of clinical cases and lack of comprehensive diagnostic analysis make it a challenge for evidence-based interpretation of clinico-cytogenomic correlations and recommendation of follow-up clinical management. Given recent advancements in genomic technologies and organized efforts by international collaborations and patient advocacy organizations, the prospective of standardized cytogenomic diagnosis and evidence-based clinical management for all patients with RCs could be achieved at an unprecedented global scale.Entities:
Keywords: cellular reprogramming; chromosome microarray analysis; chromosome therapy; clinical heterogeneity; constitutional ring chromosomes; cytogenomic heterogeneity; dynamic mosaicism; patient advocacy organizations; ring syndrome; whole-genome sequencing
Year: 2022 PMID: 36187226 PMCID: PMC9519620 DOI: 10.1016/j.xhgg.2022.100139
Source DB: PubMed Journal: HGG Adv ISSN: 2666-2477
Figure 1Major technology advancements and important clinical findings on the study of human RCs denoted along the top of a timeline for the past 60 years
Figure 2Relative frequency and case distribution of human RCs
(1) Relative frequency of ring autosomes and sex chromosomes.
(2) Correlation of relative frequency of RCs and number of protein-coding genes in each chromosome.
(3) Distribution of cases with autosomal RCs by their age of onset or at diagnosis and genders.
Cancer predisposition and related tumor-suppressor genes of constitutional RCs
| RCs | Tumor-suppressor genes | Cancers | References |
|---|---|---|---|
| 5 | – | myelodysplastic syndrome | Nozawa et al. |
| 7 | – | hyperpigmentation, melanoma | DeLozier-Blanchet et al., |
| 11 | Wilms tumor | Carella et al. | |
| 13 | retinoblastoma | Morrissette et al. | |
| 17 | neurofibromatosis type 1 | Havlovicova et al. | |
| 21 | acute myeloid leukemia | Burillo-Sanz et al., | |
| 22 | neurofibromatosis type II, meningiomas, schwannoma, | Tommerup et al., |
Web resources for constitutional ring chromosomes
| Organization | Link |
|---|---|
| All ring chromosomes | |
| A Human Ring Chromosome Registry | |
| Small supernumerary marker chromosomes | |
| UNIQUE | |
| Chromosome Disorder Outreach (CDO) | |
| Orphanet | |
| NORD | |
| Ring chromosome 14 | |
| Ring 14 International | |
| Ring14 Clinical Database | |
| Biobank collection of Ring14 biosamples | Telethon Network of Genetic Biobanks ( |
| Ring chromosome 18 | |
| Chromosome 18 Registry & Research Society | |
| Facebook group for Ring 18 in Italian | |
| Ring chromosome 20 | |
| Ring 20 Research and Support UK | |
| Ring chromosome 22 | |
| Chromosome 22 Central | |
| Facebook group for Ring 22 | |
| Yahoo group for Ring 22 | |
Figure 3A workflow for organized efforts by ICHRC to provide comprehensive cytogenomic diagnosis, resources for evidence-based interpretation and clinical management, and opportunities for collaborative research